Grant: Discovery Grants Program - Individual
University of Manitoba
$44,000.00
Ongoing research: fluorous asymmetric synthesis and new antibacterial agents
EF 2007-08
Résumé
Our ongoing research program is focused on pharmaceutical chemistry. We are working on two projects in this general area: 1) Methods for pharmaceutical discovery synthesis - Fluorous Supported Asymmetric Synthesis. Biologically active molecules are generally complex, often as a result of their detailed 3-dimensional geometries. When seeking to make new drug compounds, control over this 3-dimensional aspect of structure ("stereochemistry") is important. Drug discovery programs in pharmaceutical companies are increasingly employing automated high throughput methods, where dozens or hundreds of related molecules are synthesized in parallel. The problem is that many of the methods available for synthesizing molecules with control over stereochemistry are not amenable to this automated environment. We have devised tools to address this problem and this proposal describes our plans for developing and demonstrating these tools further. 2) New approaches to antibiotics - Carbohydrate-based Anti-Tuberculosis Compounds. TB has re-emerged as a global health threat, and the complacency that followed the first successful anti-TB drugs in the post-WWII years has only recently been replaced by awareness that the bacterium has been developing multi-drug resistance and our standard treatments may not continue to be effective much longer. There is a need for fundamentally new approaches to anti-TB drugs. We have targeted the biosynthesis of a portion of the cell wall in Mycobacterium tuberculosis. Previous work revealed three modestly active inhibitors of this biosynthetic pathway in laboratory tests, but much more needs to be learned if these leads are to be developed into really effective drug candidates suitable for testing in animals, let alone humans. This proposal describes the next step in this process of exploration.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
155310-2006
Name nom
Hultin, Philip
Department département
Chemistry
Organization id
19
Institution établissement
University of Manitoba
Province en
Manitoba
Province fr
Manitoba
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2006
Award amount
44000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
2
Nb partie
5
Application title
Ongoing research: fluorous asymmetric synthesis and new antibacterial agents
Keyword
NA
Application summary
Our ongoing research program is focused on pharmaceutical chemistry. We are working on two projects in this general area: 1) Methods for pharmaceutical discovery synthesis - Fluorous Supported Asymmetric Synthesis. Biologically active molecules are generally complex, often as a result of their detailed 3-dimensional geometries. When seeking to make new drug compounds, control over this 3-dimensional aspect of structure ("stereochemistry") is important. Drug discovery programs in pharmaceutical companies are increasingly employing automated high throughput methods, where dozens or hundreds of related molecules are synthesized in parallel. The problem is that many of the methods available for synthesizing molecules with control over stereochemistry are not amenable to this automated environment. We have devised tools to address this problem and this proposal describes our plans for developing and demonstrating these tools further. 2) New approaches to antibiotics - Carbohydrate-based Anti-Tuberculosis Compounds. TB has re-emerged as a global health threat, and the complacency that followed the first successful anti-TB drugs in the post-WWII years has only recently been replaced by awareness that the bacterium has been developing multi-drug resistance and our standard treatments may not continue to be effective much longer. There is a need for fundamentally new approaches to anti-TB drugs. We have targeted the biosynthesis of a portion of the cell wall in Mycobacterium tuberculosis. Previous work revealed three modestly active inhibitors of this biosynthetic pathway in laboratory tests, but much more needs to be learned if these leads are to be developed into really effective drug candidates suitable for testing in animals, let alone humans. This proposal describes the next step in this process of exploration.